ClinicalTrials.gov
public full text
Public Domain
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients#908834
- 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors#849278
- BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer#1072507
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors#884251
- Phase I Trial of VS-6766 Alone and in Combination With Everolimus#837659
Record · ID 1307598
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive